ScholarIQanswers from OpenAlex
AstraZeneca (France)
InstitutionResearch output, impact & collaborations
AstraZeneca (France) is a institution indexed in ScholarIQ from OpenAlex.
What is known about AstraZeneca (France)?
ScholarIQrecord summary
AstraZeneca (France) is a research organisation in Courbevoie, FR. OpenAlex records 1,424 works and 82,739 citations for it. 612 researchers list it as their most recent affiliation.
How many works does AstraZeneca (France) have?
ScholarIQindexed works
AstraZeneca (France) has 1,424 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does AstraZeneca (France) have?
ScholarIQcitation count
AstraZeneca (France) has 82,739 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at AstraZeneca (France)?
ScholarIQresearcher count
AstraZeneca (France) has 612 researchers in the ScholarIQ index.
What is the average h-index at AstraZeneca (France)?
ScholarIQavg h-index
AstraZeneca (France) has an average h-index of 48.5 in OpenAlex.
What is the ROR of AstraZeneca (France)?
ScholarIQror
The ROR for AstraZeneca (France) is on the source record.
What is the OpenAlex record for AstraZeneca (France)?
ScholarIQopenalex
The OpenAlex for AstraZeneca (France) is on the source record.
Who are the most-cited researchers behind AstraZeneca (France)?
ScholarIQtop researchers by citations
What are the most-cited papers on AstraZeneca (France)?
ScholarIQmost cited works
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Ferdinand C. Breedveld, Michael H. Weisman, Arthur F. Kavanaugh, Stanley Cohen, Karel Pavelká, Ronald van Vollenhoven, John T. Sharp, John L. Perez, G Spencer-Green
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design
Derek C. Angus, Scott Berry, Roger Lewis, Farah Al-Beidh, Yaseen M. Arabi, Wilma van Bentum-Puijk, Zahra Bhimani, Marc J. M. Bonten, Kristine Broglio, Frank M. Brunkhorst, Allen Cheng, Jean‐Daniel Chiche, Menno D. de Jong, Michelle A. Detry, Herman Goossens, Anthony Gordon, Cameron Green, Alisa M. Higgins, Sebastiaan Hullegie, Peter Krüger, François Lamontagne, Edward Litton, John C. Marshall, Anna McGlothlin, Shay McGuinness, Paul Mouncey, Srinivas Murthy, Alistair Nichol, Genevieve O’Neill, Rachael Parke, Jane Parker, Gernot Rohde, Kathy Rowan, Anne Turner, Paul J. Young, Lennie Derde, Colin McArthur, Steven Webb
Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy
Bryan T. Hennessy, Gabriel N. Hortobágyi, Roman Rouzier, Henry M. Kuerer, Nour Sneige, Aman U. Buzdar, Shu Wan Kau, Bruno D. Fornage, Ayşegül A. Şahin, Kristine Broglio, S. Eva Singletary, Vicente Valero
Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes
Massimo Cristofanilli, Ana M. González-Angulo, Nour Sneige, Shu‐Wan Kau, Kristine Broglio, Richard L. Theriault, Vicente Valero, Aman U. Buzdar, Henry M. Kuerer, Thomas A. Buccholz, Gabriel N. Hortobágyi
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
David Cella, Viktor Grünwald, Paul Nathan, Justin Doan, Homa Dastani, Fiona Taylor, Bryan Bennett, Michael DeRosa, Scott Berry, Kristine Broglio, Elmer Berghorn, Robert J. Motzer
How much of the research on AstraZeneca (France) is open access?
ScholarIQopen access share
40%OPEN ACCESS